Article Figures & Data
Figures
- FIGURE 1.
(A and B) Axial, sagittal, and coronal CT (top), PET (middle), and fused PET/CT (bottom) images of patient with clear cell renal cancer with relatively homogeneous distribution of antigen (arrows) (A) and patient with large, centrally necrotic clear cell renal cancer with marked heterogeneity of antigen distribution within mass (arrows) (B). (C) Axial CT (top), PET (middle), and fused PET/CT (bottom) images of patient with advanced clear cell renal cancer. Antigen distribution within primary tumor is heterogeneous (arrows), whereas distribution within metastatic nodes is relatively homogeneous (arrowheads).
- FIGURE 2.
Autoradiographic (A) and histologic (B) sections from patient with clear cell renal cancer. Marked heterogeneity of antibody binding seen on autoradiography correlates with areas of densest tumor cells on histology.
Tables
- TABLE 1
Measured %ID/g for Each Subject Using Digital Autoradiography, Well Counting, and PET/CT
Subject Autoradiography Well counting PET/CT 1 0.0681 0.0334 0.0453 2 0.0023 0.0015 0.0039 3 0.0018 0.0006 0.0066 4* — — — 5 0.0130 0.0094 0.0179 6 0.0452 0.0380 0.0255 7 0.1477 0.0657 0.0481 8 0.1269 0.0602 0.0391 9 0.0172 0.0413 0.0444 10 0.0093 0.0053 0.0100 11 0.1370 0.0662 0.0503 12 0.0954 0.0369 0.0268 13 0.0395 0.0124 0.0378 14 0.0032 0.0003 0.0173 15 0.0096 0.0039 0.0382 16 0.0035 0.0022 0.0061 17 0.0145 0.0043 0.0288 18 0.0062 0.0037 0.0177 19 0.0050 0.0021 0.0125 20 0.0013 0.0006 0.0028 21 0.0015 0.0012 0.0097 22 0.0046 0.0020 0.0074 23 0.0339 0.0258 0.0414 24 0.0025 0.0015 0.0035 25 0.0018 0.0008 0.0035 26 0.0091 0.0195 0.0219 ↵* Subject 4 received immunologically inactive antibody and was excluded from analysis.
Jump to section
Related Articles
Cited By...
- Evaluation of Nonpeptidic Ligand Conjugates for the Treatment of Hypoxic and Carbonic Anhydrase IX-Expressing Cancers
- Development of 124I Immuno-PET Targeting Tumor Vascular TEM1/Endosialin
- Applying PET to Broaden the Diagnostic Utility of the Clinically Validated CA19.9 Serum Biomarker for Oncology
- Radretumab Radioimmunotherapy in Patients with Brain Metastasis: A 124I-L19SIP Dosimetric PET Study
- Advances in Immuno-Positron Emission Tomography: Antibodies for Molecular Imaging in Oncology
- Bone Marrow Dosimetry Using 124I-PET